| Tbio | Voltage-dependent calcium channel subunit alpha-2/delta-3 |
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).
This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008]
This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Neurodevelopmental Disorders | 70 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 2.8e-56 |
| lung adenocarcinoma | 2716 | 9.1e-17 |
| glioblastoma | 5792 | 2.3e-09 |
| osteosarcoma | 7950 | 3.4e-08 |
| Astrocytoma, Pilocytic | 3081 | 3.4e-07 |
| tuberculosis | 2010 | 2.8e-05 |
| adult high grade glioma | 3801 | 5.5e-05 |
| medulloblastoma, large-cell | 6241 | 1.2e-04 |
| Pick disease | 1894 | 5.6e-04 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.3e-03 |
| ovarian cancer | 8520 | 1.3e-03 |
| astrocytic glioma | 2597 | 2.0e-03 |
| ependymoma | 4679 | 2.2e-03 |
| oligodendroglioma | 2850 | 1.2e-02 |
| group 4 medulloblastoma | 1855 | 1.8e-02 |
| pituitary cancer | 1972 | 2.2e-02 |
| Rheumatoid arthritis | 1191 | 2.6e-02 |
| Alzheimer's disease | 658 | 4.3e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Hereditary night blindness | 3 | 3.454 | 1.7 |
| Gingival fibromatosis | 14 | 3.329 | 1.7 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | -3.100 | 5.5e-05 |
| Alzheimer's disease | -1.300 | 4.3e-02 |
| astrocytic glioma | -2.600 | 2.0e-03 |
| Astrocytoma, Pilocytic | -2.900 | 3.4e-07 |
| atypical teratoid / rhabdoid tumor | -2.900 | 1.3e-03 |
| ependymoma | -2.800 | 2.2e-03 |
| glioblastoma | -3.100 | 2.3e-09 |
| group 4 medulloblastoma | -1.800 | 1.8e-02 |
| lung adenocarcinoma | -1.200 | 9.1e-17 |
| medulloblastoma, large-cell | -3.800 | 1.2e-04 |
| oligodendroglioma | -2.200 | 1.2e-02 |
| osteosarcoma | -2.570 | 3.4e-08 |
| ovarian cancer | -1.300 | 1.3e-03 |
| Pick disease | -2.100 | 5.6e-04 |
| pituitary cancer | 1.700 | 2.2e-02 |
| psoriasis | 1.200 | 2.8e-56 |
| Rheumatoid arthritis | -1.100 | 2.6e-02 |
| tuberculosis | 2.700 | 2.8e-05 |
MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYSGSQLLQKKY 1 - 70 KEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEFDADLQYEYFNAVLINERD 71 - 140 KDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDPAIVNGVYWSESLNKVFVDNFDRDPSLI 141 - 210 WQYFGSAKGFFRQYPGIKWEPDENGVIAFDCRNRKWYIQAATSPKDVVILVDVSGSMKGLRLTIAKQTVS 211 - 280 SILDTLGDDDFFNIIAYNEELHYVEPCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILS 281 - 350 DFNHTGQGSICSQAIMLITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAFADNLKWMACANKGFFTQ 351 - 420 ISTLADVQENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLPQAQKLTDDQGPVLMTTVAMPVFSKQNET 421 - 490 RSKGILLGVVGTDVPVKELLKTIPKYKLGIHGYAFAITNNGYILTHPELRLLYEEGKKRRKPNYSSVDLS 491 - 560 EVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLVMTNDYYYTDIKGTPFSLGVALSRGHGKYFFR 561 - 630 GNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYLKGKEPLLQCDKELIQEVLFDAVV 631 - 700 SAPIEAYWTSLALNKSENSDKGVEVAFLGTRTGLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWY 701 - 770 RRAAEQIPGSFVYSIPFSTGPVNKSNVVTASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCAS 771 - 840 LDGKCSISCDDETVNCYLIDNNGFILVSEDYTQTGDFFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRAN 841 - 910 KESSDGAHGLLDPYNAFLSAVKWIMTELVLFLVEFNLCSWWHSDMTAKAQKLKQTLEPCDTEYPAFVSER 911 - 980 TIKETTGNIACEDCSKSFVIQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIRYNESLKCERLKAQKIRR 981 - 1050 RPESCHGFHPEENARECGGAPSLQAQTVLLLLPLLLMLFSR 1051 - 1091 //
